Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial

医学 恶心 内科学 催眠药 不利影响 联合疗法 肿瘤科 实体瘤疗效评价标准 临床研究阶段 药代动力学 癌症 药理学 胃肠病学 毒性
作者
Amita Patnaik,Timothy A. Yap,Hyun Cheol Chung,Maria J. de Miguel,Yung‐Jue Bang,Chia‐Chi Lin,Wu‐Chou Su,Antoîne Italiano,Kay Hoong Chow,Anna M. Szpurka,Danni Yu,Yumin Zhao,Michelle Carlsen,Shelly Schmidt,Burkhard Vangerow,Leena Gandhi,Xiaojian Xu,Johanna C. Bendell
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:27 (5): 1267-1277 被引量:45
标识
DOI:10.1158/1078-0432.ccr-20-2821
摘要

Abstract Purpose: This phase Ia/Ib PACT study evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of a new programmed cell death ligand 1 (PD-L1) inhibitor, LY3300054, as monotherapy or in combination with ramucirumab, abemaciclib, or merestinib (a type II MET kinase inhibitor) in patients with advanced, refractory solid tumors (NCT02791334). Patients and Methods: Patients were enrolled into cohorts of escalating LY3300054 dose (phase Ia) as monotherapy (N = 15) or combined with ramucirumab (N = 10), abemaciclib (N = 24), or merestinib (N = 12). The phase Ib dose expansion enrolled 8 patients with melanoma in the monotherapy arm and 12 patients with pancreatic cancer in the merestinib combination arm. Combination treatments were administered concurrently from day 1 of each cycle. A 14-day lead-in abemaciclib arm was also explored. Primary endpoints were dose-limiting toxicity (DLT) and safety. Results: Treatment-related adverse events included fatigue and nausea in the monotherapy arm (13% for each), hypothyroidism (30%) in the ramucirumab arm, diarrhea (54%) in the abemaciclib arm, and nausea (25%) in the merestinib arm. DLTs associated with hepatoxicity were observed in 3 of 4 patients in the abemaciclib lead-in cohorts. No DLTs or grade 3 or 4 hepatoxicity were reported in the concurrent abemaciclib arm. Pharmacokinetic characteristics were comparable with other PD-L1 inhibitors. One patient in each arm experienced a partial response per RECIST v1.1 lasting ≥7 months. Conclusions: LY3300054 was well tolerated without unexpected safety concerns when administered alone or concurrently with ramucirumab, abemaciclib, or merestinib. Lead-in abemaciclib before combining with LY3300054 was not feasible due to hepatotoxicity. Durable clinical benefits were seen in all regimens.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Lucky.完成签到 ,获得积分0
3秒前
欢喜平凡完成签到,获得积分10
4秒前
孑然完成签到 ,获得积分10
5秒前
6秒前
清淮完成签到 ,获得积分10
6秒前
王哈哈完成签到 ,获得积分10
9秒前
范yx发布了新的文献求助10
12秒前
老迟到的断秋完成签到,获得积分10
14秒前
19秒前
破晓完成签到,获得积分10
24秒前
shuang完成签到,获得积分10
26秒前
淮安石河子完成签到 ,获得积分10
26秒前
dgqyushen完成签到,获得积分10
26秒前
鳗鱼柚子完成签到 ,获得积分10
28秒前
江海阔发布了新的文献求助10
30秒前
dongdong完成签到 ,获得积分10
32秒前
四叶草完成签到 ,获得积分10
33秒前
崔秀萍完成签到 ,获得积分10
34秒前
38秒前
水煮电吹风的应助被Albafika采纳,获得10
39秒前
rzxhygr完成签到,获得积分10
41秒前
江海阔完成签到,获得积分10
43秒前
高贵嘉懿完成签到,获得积分10
44秒前
超帅晓槐完成签到,获得积分10
45秒前
长情以蓝完成签到 ,获得积分10
45秒前
紫熊发布了新的文献求助10
50秒前
56秒前
儒雅傲之完成签到,获得积分10
57秒前
河不柃完成签到,获得积分10
58秒前
wwwwcom完成签到,获得积分10
1分钟前
小刺猬完成签到,获得积分10
1分钟前
沉静的便当完成签到 ,获得积分10
1分钟前
Flying_Time完成签到,获得积分10
1分钟前
哈哈哈完成签到,获得积分10
1分钟前
jazz完成签到,获得积分10
1分钟前
1分钟前
asdf完成签到,获得积分10
1分钟前
Xiao_Fu完成签到,获得积分10
1分钟前
Adrianlee完成签到,获得积分10
1分钟前
SCIReader1112完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185520
求助须知:如何正确求助?哪些是违规求助? 9574253
关于积分的说明 21834635
捐赠科研通 7783146
什么是DOI,文献DOI怎么找? 3434577
关于科研通互助平台的介绍 2558951
邀请新用户注册赠送积分活动 2481357